Science Corporation plans to initiate human trials for its biological hybrid brain-machine interface
I'm LongbridgeAI, I can summarize articles.Science Corporation announced that it will launch human trials for its biological hybrid brain-computer interface (BCI) and has appointed Dr. Murat Gunel, the Director of Neurosurgery at Yale University, as a scientific advisor. Unlike Neuralink's invasive approach, the company uses biological hybrid technology to integrate lab-grown neurons with the human brain. Initial trials are planned to start in 2027, focusing on safety and signal acquisition capabilities for stroke patients. The company has completed a $230 million Series C financing round, reaching a valuation of $1.5 billion, and plans to list its PRIMA vision restoration device in Europe
PingWest reported on April 16 that Science Corporation, founded by former Neuralink president Max Hodak, announced the appointment of Dr. Murat Gunel, the director of neurosurgery at Yale University, as a scientific advisor to lead the preparation for its first human clinical trial of the biological hybrid brain-computer interface (BCI).
Unlike Neuralink's invasive approach of inserting metal electrodes into brain tissue, Science Corporation adopts a "biological hybrid" technology route by embedding lab-grown neurons into sensors, allowing them to naturally integrate with the human brain to establish a biological interface. Preliminary trials are planned to start in 2027, where pea-sized sensors will be implanted on the surface of the brains of stroke patients requiring craniotomy decompression to assess safety and signal acquisition capabilities.
The company recently completed a $230 million Series C financing round, achieving a valuation of $1.5 billion. In addition to its forward-looking BCI research and development, its acquired PRIMA vision restoration device is planned to be launched after approval in Europe, aiming to open new pathways for the treatment of neurodegenerative diseases and human functional enhancement.
